You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Novel Nonsteroidal Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease in Type 2 Diabetes: A Step Change in Treatment?

  • Authors: Pantelis Sarafidis, MD, MSc, PhD; Janet B. McGill, MD, MA, FACP; Katharina Schütt, MD, FESC; Beatriz Fernandez-Fernandez, MD, PhD
  • CME / ABIM MOC Released: 1/24/2023
  • Valid for credit through: 1/24/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for a global audience of primary care physicians/family doctors, nephrologists, and diabetologists/endocrinologists.

The goal of this activity is for learners to improve their awareness of the serious health risks associated with CKD in patients with T2D and the availability of novel treatment options shown to reduce the risk of associated complications.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of action of emerging treatment options for CKD in T2D
    • Clinical benefits of selective nonsteroidal mineralocorticoid receptor antagonists (MRAs) for T2D patients with CKD 
    • Safety aspects of novel selective nonsteroidal MRAs in CKD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Pantelis Sarafidis, MD, MSc, PhD

    Associate Professor of Nephrology
    Aristotle University of Thessaloniki
    Thessaloniki, Greece

    Disclosures

    Pantelis Sarafidis, MD, MSc, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Bayer; Innovis Pharma; Menarini; Recor Medical
    Speaker or member of speakers bureau for: Astellas; AstraZeneca; Bayer; Boehringer Ingelheim; Genesis Pharma; Menarini; Sanofi; Winmedica
    Research funding from: AstraZeneca; Boehringer Ingelheim; Elpen Pharmaceuticals; Servier

Faculty

  • Janet B. McGill, MD, MA, FACP

    Professor of Medicine
    Washington University School of Medicine
    St Louis, Missouri, United States

    Disclosures

    Janet B. McGill, MD, MA, FACP, has the following relevant financial relationships:
    Consultant or advisor for: Bayer; Boehringer Ingelheim; MannKind; Novo Nordisk
    Research funding from: Funding to institution from Beta Bionics; Novo Nordisk

  • Katharina Schütt, MD, FESC

    Department of Internal Medicine I (Cardiology)
    University Hospital RWTH Aachen
    Aachen, Germany

    Disclosures

    Katharina Schütt, MD, FESC, has the following relevant financial relationships:
    Consultant or advisor for: AstaZeneca; Bayer; Boehringer Ingelheim
    Speaker or member of speakers bureau for: Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Eli Lilly and Company; Merck Sharp & Dohme; Novartis; Novo Nordisk

  • Beatriz Fernandez-Fernandez, MD, PhD

    Associate Professor
    Department of Medicine
    Faculty of Medicine
    Universidad Autónoma de Madrid
    Madrid, Spain

    Disclosures

    Beatriz Fernandez-Fernandez, MD, PhD, has no relevant financial relationships.

Editor

  • Rita Moreira Da Silva, PhD, MA, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Rita Moreira Da Silva, PhD, MA, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Novel Nonsteroidal Mineralocorticoid Receptor Antagonists for Chronic Kidney Disease in Type 2 Diabetes: A Step Change in Treatment?

Authors: Pantelis Sarafidis, MD, MSc, PhD; Janet B. McGill, MD, MA, FACP; Katharina Schütt, MD, FESC; Beatriz Fernandez-Fernandez, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 1/24/2023

Valid for credit through: 1/24/2024

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print